Hanahan: Evident for decades - after a daylong discussion this '00 Cell https://t.co/lrPxpUn5Lc then '11 https://t.co/OUlsvDF02I #AACR16
8:06am April 19th 2016 via Hootsuite
HanahaSo much complexity - organ sites, cell types, mutations, passengers, effects, rate of progression, survival, response, relapse #AACR16
8:03am April 19th 2016 via Hootsuite
Douglas Hanahan (Swiss Inst. Cancer Res (ISREC), Lausanne, Switzerland) Hallmarks of Cancer: From Concepts to Combinatorial Therapies AACR16
8:02am April 19th 2016 via Hootsuite
Theranos Is Subject of Criminal Probe by U.S. - WSJ https://t.co/DX0ibfosZF
6:43am April 19th 2016 via Hootsuite
Email in reply to my #AACR16 out of office: "You should change your signature to: Dale 'I spend 90% of my time at conferences' Yuzuki"
6:42am April 19th 2016 via Hootsuite
.@CePeterman Yes Carol it is super whenever someone says to me IRL "Hey I recognize you from Twitter!'
6:39am April 19th 2016 via Hootsuite in reply to CePeterman
Illumina Lowers Revenue Guidance on Disappointing Europe Results - WSJ https://t.co/obkEVA2k0j
12:12am April 19th 2016 via Hootsuite
.@precisioncancer has a neat 3D VR game here at #AACR16 https://t.co/iqTcE8CoQC
12:15pm April 18th 2016 via Hootsuite
Carpten: A3:What trial design to use, how to randomize? Is PM better? In what instances or cases cp to std of care? #AACR16
8:53am April 18th 2016 via Hootsuite
Carpten:A2: In some pts, PFS will increase. Today not enough information; today needs to be done as clinical trials. BATTLE? MATCH? #AACR16
8:52am April 18th 2016 via Hootsuite
Q: W/o clin trial data, eg SHIVA? Is it too early? Carpten: Agree to need to measure if PM is better than std of care. #AACR16
8:51am April 18th 2016 via Hootsuite
Carpten: But cholangiocarcinoma, absolutely different paths to take. #AACR16
8:49am April 18th 2016 via Hootsuite
Carpten: Concludes 'Absolutely the right choice for some patients, not for everyone'. E.g. a pancreatic cancer pt, KRAS but no path #AACR16
8:48am April 18th 2016 via Hootsuite
Carpten: Long list to rethink: clin testing, drug dev, trial design, education, outcome measurement, reimbursement, pt outreach #AACR16
8:47am April 18th 2016 via Hootsuite
Carpten: Can this high-complexity testing fit into existing clinical paradigm? Or do we need to rethink the entire system? #AACR16
8:46am April 18th 2016 via Hootsuite
Carpten: Looking at population germline variants, affecting drug rules by population, where some variants more prevelant in some gps #AACR16
8:44am April 18th 2016 via Hootsuite
Carpten: Precision oncology: race (as a social construct, affecting access, reimbursement) and ancestry (genetics), corr to disease #AACR16
8:43am April 18th 2016 via Hootsuite
Carpten: Also serious consequences for Rx choice for pt., given the genetic cardiac risk. #AACR16
8:42am April 18th 2016 via Hootsuite
Carpten: Germline var's "To report or not" - 17y.o. found tumor somatic, but also impt germline cardiac var affecting entire family #AACR16
8:41am April 18th 2016 via Hootsuite
Carpten: Liquid biopsy ctDNA for high genetic risk, or monitor residual disease post-Rx, they are doing with L Diaz (PGDx) #AACR16
8:39am April 18th 2016 via Hootsuite
Carpten: PDX avatars used to look at use of combination Rx to move into PhI clinical trials. #AACR16
8:38am April 18th 2016 via Hootsuite
Carpten: Onto microbiome: Figure from '13 review https://t.co/Ug1RfaSHTX Also looking at Patient-derived Xenograft avatars #AACR16
Carpten: Perhaps cycling between pertuzimab and erlotinib, or a combination Rx, may have been helpful. Tumor heterogeneity... #AACR16
8:36am April 18th 2016 via Hootsuite
Carpten: Erlotinib resulted in response, progression, 3rd biopsy: EGFR went way. No combination given, just 2 clones battling it out #AACR16
8:35am April 18th 2016 via Hootsuite
Carpten: Also in same individual inactivating mut; decided course of action; dramatic 4-mo response. 2nd biopsy CNV new EGFR ampl #AACR16
8:34am April 18th 2016 via Hootsuite
Carpten: Found a novel NRG1 fusion (w/RBPMS); NRG1 inactivates ERBB recepter, FGFR activation in cholangiocarcinoma #AACR16
8:33am April 18th 2016 via Hootsuite
Carpten: Metastatic Cholangiocarcinoma '14 https://t.co/EmUJq7yVwn reviews unique oncogenic fusions, how detection impacted trtmt #AACR16
8:31am April 18th 2016 via Hootsuite
Carpten: Lab has been CLIA- and CAP-accredited, also submitted an IND to the FDA in conjunction with @SU2C #AACR16
8:28am April 18th 2016 via Hootsuite
Carpten: Their reporting on GBM - looking whether a drug can cross blood-brain barrier; literature-based. #AACR16
8:27am April 18th 2016 via Hootsuite
Carpten: Nature Gen Review from Mar '16 https://t.co/0XbTfqsQAc 'Translating RNA-Seq into clincal diagnostics' #AACR16
Carpten: Relevant fusions, generated in collab w/@illumina in-vitro transcribed RNAs '14 BMC https://t.co/Mfzc2P8QQI #AACR16
8:25am April 18th 2016 via Hootsuite
Carpten: Shows sens and spec using ERCC spike-ins as part of validaitons; detecting RNA spp w/Affy chip cp to RNA-seq data correl. #AACR16
8:23am April 18th 2016 via Hootsuite
Carpten: Built out, tested 3 algorithms for technical validation (ExomeCNV, TGen, TGen BAF tools) genomewide #AACR16
8:22am April 18th 2016 via Hootsuite
Carpten: Doing dilutions from 0% to 100% between lines, can look at 5% tumor need 400x coverage at 80% power #AACR16
8:21am April 18th 2016 via Hootsuite
Carpten: ID'd 450 mutations across 3 different groups; in press now at Sci Reports, worked with #GIAB (NIST Genome in a Bottle) #AACR16
8:20am April 18th 2016 via Hootsuite
Carpten:Highlights Craig's work at TGEN with bioinformatics, workflow. Reiterated this '10 work https://t.co/wUJH0Ii3iz in theirs #AACR16
8:19am April 18th 2016 via Hootsuite
Carpten: Can access allele-specific expresion from RNA; overexpression of neoantigens, gene fusions #AACR16
8:17am April 18th 2016 via Hootsuite
Carpten: Have a 'hybrid somatic genome design' - capturing structural events genome-wide (xloc's, inversions); can do CNVs of exons #AACR16
Carpten: FP's can cause 'very toxic drugs given to patients' that need to be avoided. #AACR16
8:16am April 18th 2016 via Hootsuite
Carpten: Tumor/normal sequencing: 'high risk of false-positives using filtering based on known variants' #AACR16
8:15am April 18th 2016 via Hootsuite
Carpten: Discusses sample considerations / quality, how to sample the 'entirety'; needle biopsies 'may be all we have' #AACR16
Carpten: Impt aspect - clinical portal; have a CLIA LIMS workflow mgmt, who accesses what. #AACR16
8:14am April 18th 2016 via Hootsuite
Carpten: With David Craig at TGEN, lays out a flowchart for precision oncology trials. Both DNA, RNA from tumor, germline. WGS #AACR16
8:12am April 18th 2016 via Hootsuite
Carpten: 'with this single technology at unprecedented resolution';highlights this '16 paper (PREDICT) https://t.co/qXmXGNuVo3 #AACR16
8:11am April 18th 2016 via Hootsuite
Carpten: Multiple technologies needed before (CNVs via arrays, FISH via cytology) vs how NGS 'can make all measurements' #AACR16
8:10am April 18th 2016 via Hootsuite
Carpten: Starts with a wide overview of the rationale of Precision Medicine, and the types of somatic evants that occur #AACR16
8:08am April 18th 2016 via Hootsuite
John Carpten (Univ So Calif CA): Precision Oncology: Opportunities and Challenges #AACR16
Previewing the American Association for Cancer Research 2016 Conference #AACR16 |@SeraCare blog Genomic Precision https://t.co/mQZLn969UA
6:51am April 18th 2016 via Hootsuite
Zhang: Now in-press, solved crystal structures; now can optimize the Cpf1. Novel second nuclease domain ID'd #AACR16
12:15pm April 17th 2016 via Hootsuite
Zhang: Cpf1 may allow for multiple tandem guide RNAs, thus multiplex genome editing possible. Shows unpublished results w/4 genes #AACR16
12:13pm April 17th 2016 via Hootsuite
